5-(3-methylisoquinolin-6-yl)-1,3,4-thiadiazol-2-amine | 885223-51-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 5-(3-methylisoquinolin-6-yl)-1,3,4-thiadiazol-2-amine
• CAS: 885223-51-8
• 化学式: C₁₂H₁₀N₄S
• 分子量: 242.304
• InChiKey: CFYLOIWNNSCZNN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  92.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-(3-methylisoquinolin-6-yl)-1,3,4-thiadiazol-2-amine 、 BOC-L-4-三氟甲基苯丙氨酸 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics

  摘要：

  A series of 2-aminothiadiazole of inhibitors of AKT1 is described. SAR relationships are discussed, along with selectivity for protein kinase A (PKA) and cyclin-dependent kinase 2 (CDK2). Moderate selectivity observed in several compounds for AKT1 versus PKA is rationalized by X-ray crystallographic analysis. Key compounds showed activity in cellular assays measuring phosphorylation of two AKT substrates, PRAS40 and FKHRL1. Compound 30 was advanced to a mouse liver PD assay, where it showed dose-dependent inhibition of AKT activity, as measured by the inhibition of phospho-PRAS40. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.046
• 作为产物：
  描述：

  3-甲基-6-异喹啉羧酸 、 氨基硫脲 在 polyphosphoric acid 作用下， 生成 5-(3-methylisoquinolin-6-yl)-1,3,4-thiadiazol-2-amine
  参考文献：
  名称：

  2-Aminothiadiazole inhibitors of AKT1 as potential cancer therapeutics

  摘要：

  A series of 2-aminothiadiazole of inhibitors of AKT1 is described. SAR relationships are discussed, along with selectivity for protein kinase A (PKA) and cyclin-dependent kinase 2 (CDK2). Moderate selectivity observed in several compounds for AKT1 versus PKA is rationalized by X-ray crystallographic analysis. Key compounds showed activity in cellular assays measuring phosphorylation of two AKT substrates, PRAS40 and FKHRL1. Compound 30 was advanced to a mouse liver PD assay, where it showed dose-dependent inhibition of AKT activity, as measured by the inhibition of phospho-PRAS40. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.046

文献信息

• Thiadiazole compounds and methods of use
  申请人：Monenschein Holger

  公开号：US20080255145A1

  公开（公告）日：2008-10-16

  The invention relates to thiadiazole compounds useful for treating diseases mediated by protein kinase B (PKB). The invention also relates to the therapeutic use of such thiadiazole compounds and compositions thereof in treating disease states associated with abnormal cell growth, cancer, inflammation, and metabolic disorders.

  本发明涉及一种对蛋白激酶B（PKB）介导的疾病有用的噻二唑化合物。本发明还涉及在治疗与异常细胞生长、癌症、炎症和代谢障碍有关的疾病状态中使用这种噻二唑化合物及其组合物的治疗用途。
• THIADIAZOLE COMPOUNDS AND METHODS OF USE
  申请人：Amgen, Inc

  公开号：EP1809282B1

  公开（公告）日：2013-01-09
• US7354944B2
  申请人：——

  公开号：US7354944B2

  公开（公告）日：2008-04-08
• US7700636B2
  申请人：——

  公开号：US7700636B2

  公开（公告）日：2010-04-20
• US7919514B2
  申请人：——

  公开号：US7919514B2

  公开（公告）日：2011-04-05